Brief: Dri Healthcare Comments On FDA Approval And Our Increased Investment In Kalvista Pharmaceuticals' Ekterly®
08/07/2025 12:28
July 8 (Reuters) - Dri Healthcare Trust DHT_u.TO: DRI HEALTHCARE COMMENTS ON FDA APPROVAL AND OUR INCREASED INVESTMENT IN KALVISTA PHARMACEUTICALS' EKTERLY® (SEBETRALSTAT) Source text: ID:nCNWJM530a Further company coverage: [DHT_u.TO] ((Reuters.Briefs@thomsonreuters.com;))
Recent news on DRI Healthcare Trust
See all newsCanada's DRI Healthcare Trust Q1 total income rises
Brief: DRI Healthcare Trust Q1 Total Income USD 50.561 Million
Canada's DRI Healthcare annual income hits record, raises distribution
Brief: DRI Healthcare Trust Q4 Total Income USD 61.686 Million
Brief: Dri Healthcare Trust Announces Preferred Securities Refinancing